Notícias Eulerpool Viridian Therapeutics

Viridian Therapeutics Eulerpool-AFX

Viridian Therapeutics Notícias de ações

Viridian Therapeutics é observado por muitos jornalistas e investidores em todo o mundo. As notícias mais recentes de Viridian Therapeutics nós reunimos aqui.

• 25 de julho ·

  Yahoo
  Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
• 25 de julho ·

  Thefly.com
  Viridian Therapeutics completes enrollment in THRIVE-2 trial
• 18 de julho ·

  TipRanks
  Buy Rating for Viridian Therapeutics on VRDN-001 Clinical Advancements and Market Potential
• 16 de julho ·

  Thefly.com
  Wedbush reveals three potential buyout targets for Biogen
• 3 de julho ·

  Yahoo
  Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 20 de junho ·

  TipRanks
  Viridian Therapeutics’ Shareholders Approve Equity Plan Expansion
• 12 de junho ·

  SeekingAlpha
  Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year
• 12 de junho ·

  TipRanks
  Ladenburg Thalmann & Co. Remains a Hold on Viridian Therapeutics (VRDN)
• 11 de junho ·

  TipRanks
  Analysts Offer Insights on Healthcare Companies: Longboard Pharmaceuticals (LBPH) and Viridian Therapeutics (VRDN)
• 11 de junho ·

  Yahoo
  Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease